help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This version published online on July 3, 2007
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2007-0225
A more recent version of this article appeared on September 1, 2007
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
92/9/3542    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pilli, T.
Right arrow Articles by Pacini, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pilli, T.
Right arrow Articles by Pacini, F.
Related Collections
Right arrow Thyroid
Right arrow Endocrine Oncology

Submitted on January 30, 2007
Accepted on June 22, 2007

A comparison of 1850 MBq (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant TSH-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer

Tania Pilli, Ernesto Brianzoni, Francesca Capoccetti, Maria Grazia Castagna, Sara Fattori, Angela Poggiu, Gloria Rossi, Francesca Ferretti, Elisa Guarino, Luca Burroni, Angelo Vattimo, Claudia Cipri, and Furio Pacini*

Department of Internal Medicine, Endocrinology & Metabolism and Biochemistry, Section of Endocrinology & Metabolism; Department of Radiology, Section of Nuclear Medicine, University of Siena; Unit of Nuclear Medicine and Department of Fisica Sanitaria, Hospital of Macerata; Italy

* To whom correspondence should be addressed. E-mail: pacini8{at}unisi.it.

Objective: Recently, a multicenter study in differentiated thyroid cancer (DTC) patients showed that 3700 MBq of 131I after rhTSH had successful thyroid ablation rate similar to that obtained after thyroid hormone withdrawal. We investigated whether 1850 MBq of 131I have similar successful rate to 3700 MBq in patients prepared with rhTSH.

Design: Seventy-two patients with DTC were randomly assigned to receive 1850 MBq (group A, n: 36) or 3700 MBq (group B, n: 36) of 131I after rhTSH. One injection of 0.9 mg of rhTSH was administered for two consecutive days; 131I therapy was delivered 24 hours after the last injection followed by a post-therapy whole body scan (WBS). Successful ablation was assessed 6-8 months later.

Results: Successful ablation (no visible uptake in the diagnostic WBS after rhTSH stimulation) was achieved in 88.9% of group A and group B patients. Basal and rhTSH-stimulated serum Tg was undetectable (<1 ng/ml) in 78.9% of group A and 66.6% of group B patients (p=0.46). Similar rates of ablation were obtained in both groups also in patients with node metastases.

Conclusion: Therapeutic 131I activities of 1850 MBq are equally effective as 3700 MBq for thyroid ablation in DTC patients prepared with rhTSH, even in the presence of node metastases.
Key words: thyroid cancer • rhTSH • thyroglobulin • radioiodine • thyroid ablation




This article has been cited by other articles:


Home page
 JNMHome page
P. W. Rosario, M. A. R. Borges, and S. Purisch
Preparation with Recombinant Human Thyroid-Stimulating Hormone for Thyroid Remnant Ablation with 131I Is Associated with Lowered Radiotoxicity
J. Nucl. Med., November 1, 2008; 49(11): 1776 - 1782.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. Remy, I. Borget, S. Leboulleux, N. Guilabert, F. Lavielle, J. Garsi, C. Bournaud, S. Gupta, M. Schlumberger, and M. Ricard
131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients
J. Nucl. Med., September 1, 2008; 49(9): 1445 - 1450.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society